BioSpace

Novo’s CagriSema drives more than 20% weight loss at lower doses

As Novo awaits an FDA decision for its next-gen obesity asset, the company has presented more data at ObesityWeek that could help buoy sentiment on the amylin/GLP-1 combination that disappointed investors a couple of years ago.

By BioSpace

1 min read
Novo’s CagriSema drives more than 20% weight loss at lower doses
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights